| Bid | 1.64 |
| Market Cap | 45.15M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.76 |
| PE Ratio (ttm) | -0.93 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.65 |
| Volume | 172,577 |
| Avg. Volume (20D) | 3,077,850 |
| Open | 1.63 |
| Previous Close | 1.60 |
| Day's Range | 1.60 - 1.70 |
| 52-Week Range | 0.81 - 3.02 |
| Beta | undefined |
About ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company ...
Analyst Forecast
According to 1 analyst ratings, the average rating for ITRM stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 204.75% from the latest price.
2 months ago · seekingalpha.com
Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript)Iterum Therapeutics plc (NASDAQ:ITRM ) U.S. FDA Approval of ORLYNVAH October 28, 2024 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs & Secretary Corey Fishman - President, Directo...